ROBERT ASA HORN
Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology SAN ANTONIO, TX NPI 1629426705
Browse related groups: Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology TX Amgen Inc. All categories
General Payments — all program years on this page
$2,239.86
- Category: General Payments
- Program years: PY2019–2024
- Record count: 35
- As of (CMS publication): 2026-01-23
Latest program year (PY2024): $503.64 across 8 records · disputed records: 0
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How this figure is calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
Latest program year (PY2024) · sorted by reported total.
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $503.64 | 8 |
By paying entity
Latest program year (PY2024) · sorted by reported total.
| Paying entity | Amount | Records |
|---|---|---|
| Amgen Inc. | $124.99 | 1 |
| Genmab U.S., Inc. | $124.99 | 1 |
| Janssen Scientific Affairs, LLC | $88.48 | 1 |
| GENZYME CORPORATION | $74.29 | 1 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $59.25 | 2 |
| Karyopharm Therapeutics Inc. | $17.85 | 1 |
| Astellas Pharma US Inc | $13.79 | 1 |
By program year
Records — PY2024 (8)
| Record ID | Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Source |
|---|---|---|---|---|---|---|---|
| 1078860721 | Janssen Scientific Affairs, LLC | $88.48 | 04/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1086948445 | Novartis Pharmaceuticals Corporation | $25.04 | 05/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1086948447 | Novartis Pharmaceuticals Corporation | $34.21 | 06/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1115732130 | Amgen Inc. | $124.99 | 10/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1126831322 | Genmab U.S., Inc. | $124.99 | 09/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1139442304 | Astellas Pharma US Inc | $13.79 | 11/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1140012926 | GENZYME CORPORATION | $74.29 | 05/31/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1145536089 | Karyopharm Therapeutics Inc. | $17.85 | 10/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
Provenance & corrections
- Dataset: CMS Open Payments — General Payments
- Source: CMS Open Payments dataset (bulk file)
- Publisher of source data: Centers for Medicare & Medicaid Services
- Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.